Griseofulvin
Generic name
Griseofulvin
Brand name
ATC Code
D01BA01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Tinea capitis |
|---|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Oestrogen-like effects (on the genitalia and breasts)
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions
No information available on specific warnings and precautions in children.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
ANTIFUNGALS FOR SYSTEMIC USE
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
References
- González U, et al, Systemic antifungal therapy for tinea capitis in children., Cochrane Database Syst Rev, 2007, 17(4), CD004685
- Bennet ML et al, Oral griseofulvin remains the treatment of choice for tinea capitis in children., Pediatr Dermatol, 2000, 17(4), 325-6
- Elewski BE et al, Terbinafine hydrochloride oral granules versus oral griseofulvin suspension in children with tinea capitis: results of two randomized, investigator-blinded, multicenter, international, controlled trials., J Am Acad Dermatol, 2008, 59(1), 41-54
- Kakourou T, Guidelines for the management of tinea capitis, Pediatr Dermatol, 2010, 27(3), 226-8.
Changes
Therapeutic Drug Monitoring
Overdose
